Conversation with The Cancer Letter

Pisters: “Trust is broken when a grant reviewer decides that an idea should be better done elsewhere”

As MD Anderson investigates reports of wrongdoing by its faculty members, it does so with full understanding that the stakes are as high as it gets: the integrity of the NIH peer review system, MD Anderson's good name, and the future of cancer research.

April 26, 2019

Vol.45 No.17

By Paul Goldberg

Conversation with The Cancer Letter

Fred Hirsch: New center focuses Mount Sinai’s thoracic oncology programs

Every year, 800 to 1,000 new patients get referred to The Tisch Cancer Insitute of Mount Sinai lung cancer specialists.

April 12, 2019

Vol.45 No.15

By Paul Goldberg

Conversation with The Cancer Letter Free

Penn’s Brooks: Surgeons should study oncologic endpoints for years, not just 30-day outcomes

The University of Pennsylvania was planning a short-term trial for robotic mastectomies, but after an FDA advisory, investigators decided to revise that protocol to include assessment of cancer-related outcomes, said Ari Brooks, director of endocrine and oncologic surgery, director of the Integrated Breast Center at the University of Pennsylvania Health System, and professor of clinical surgery at Penn Medicine.

April 05, 2019

Vol.45 No.14

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

MD Anderson’s Hunt and Selber: We will study immediate and long-term outcomes of robotic mastectomy in a prospective trial

Robotic mastectomy deserves to be studied, because the procedure may improve cancer-related outcomes, surgeons at MD Anderson Cancer Center say.

April 05, 2019

Vol.45 No.14

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

MSK’s Kirstein: Robotic mastectomy not demonstrated to be safe for treatment or prevention of breast cancer

The Breast Surgical Service at Memorial Sloan Kettering Cancer Center has decided not to adopt—or study—robotic surgical devices in mastectomies, said Laurie Kirstein, a breast surgical oncologist at MSK.

April 05, 2019

Vol.45 No.14

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Lee Schwartzberg tells us how three practices banded together to adapt to today’s cancer care and data revolution

Community oncology needs to adapt to the era of precision oncology and Big Data, said Lee Schwartzberg, executive director of Memphis-based West Cancer Center, who was recently named chief medical officer of OneOncology, a partnership between three oncology practices located in Tennessee and New York.

March 29, 2019

Vol.45 No.13

By Matthew Bin Han Ong

Conversation with The Cancer Letter

James Willson: CPRIT is money well spent

Advocates of renewing the Cancer Prevention and Research Institute of Texas argue that the agency is a good investment for the state.

March 22, 2019

Vol.45 No.12

By Claire Dietz and Matthew Bin Han Ong

Conversation with The Cancer Letter Free

TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”

The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:

March 15, 2019

Vol.45 No.11

By Paul Goldberg

Conversation with The Cancer Letter Free

St. Jude’s Roberts: “No single institution can maximize cures and minimize toxicities alone”

Matthew Ong spoke with Charles Roberts.

March 08, 2019

Vol.45 No.10

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

CHOP’s Resnick: Big data will transition from research to the standard of care in the clinic

Matthew Ong spoke with Adam Resnick.

March 08, 2019

Vol.45 No.10

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Pisters: “Trust is broken when a grant reviewer decides that an idea should be better done elsewhere”

Fred Hirsch: New center focuses Mount Sinai’s thoracic oncology programs

Penn’s Brooks: Surgeons should study oncologic endpoints for years, not just 30-day outcomes

MD Anderson’s Hunt and Selber: We will study immediate and long-term outcomes of robotic mastectomy in a prospective trial

MSK’s Kirstein: Robotic mastectomy not demonstrated to be safe for treatment or prevention of breast cancer

Lee Schwartzberg tells us how three practices banded together to adapt to today’s cancer care and data revolution

James Willson: CPRIT is money well spent

TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”

St. Jude’s Roberts: “No single institution can maximize cures and minimize toxicities alone”

CHOP’s Resnick: Big data will transition from research to the standard of care in the clinic

Renew today!

Subscriber content

Never miss an issue!

Login